Skip to main content

Table 1 Characteristics of adults with current asthma: included and excluded from phenotype classification, and stratified by single or multiple phenotypes

From: Having concomitant asthma phenotypes is common and independently relates to poor lung function in NHANES 2007–2012

Demographic characteristics

n (wt%)

Included subjects

n = 634

Excluded subjects

n = 425

p value*

Single phenotype†

n = 271

Multiple phenotypes†

n = 286

p value*

Female gender

410 (63)

261 (64)

0.93

174 (64)

192 (66)

0.68

Age (yrs), median (Q1–Q3)

44.0 (31.0–57.0)

48.9 (33.7–68.0)

< 0.001

42.0 (30.0–55.0)

47.5 (34.0–60.0)

0.003

BMI (kg/m2), median (Q1–Q3)

30.8 (25.4-35.9)

31.4 (24.4-35.7)

0.99

28.7 (24.2–35.0)

33.7 (30.7–39.0)

< 0.001

Obesity status

 Underweight (≤ 18.4 kg/m2)

2 (0.3)

13 (4)

< 0.001

1 (0.2)

1 (0.5)

0.41

 Normal (18.5–24.9 kg/m2)

142 (25)

98 (27)

0.44

78 (30)

20 (8)

< 0.001

 Overweigh (25–29.9 kg/m2)

151 (26)

77 (19)

0.07

80 (32)

38 (15)

< 0.001

 Obese (≥ 30 kg/m2)

339 (49)

187 (49)

0.94

112 (38)

227 (77)

< 0.001

Race and/or ethnicity

 Hispanic

105 (8)

85 (10)

0.30

38 (8)

56 (9)

0.24

 Non-Hispanic white

323 (74)

184 (63)

0.005

135 (72)

138 (72)

0.93

 Non-Hispanic black

167 (14)

117 (18)

0.03

76 (14)

81 (16)

0.71

 Other Race

39 (4)

39 (7)

0.06

22 (6)

11 (3)

0.11

Smoking status

 Current smoker

199 (29)

114 (32)

0.40

89 (31)

87 (27)

0.46

 Ex-smoker

163 (29)

98 (23)

0.13

56 (20)

89 (36)

0.003

 Non-smoker

272 (43)

154 (45)

0.53

126 (49)

110 (37)

0.02

Education

 ≥ High school

478 (84)

225 (69)

< 0.001

205 (86)

209 (81)

0.13

Asthma-related medication‡

 Reliever medication**

276 (41)

202 (48)

0.16

113 (37)

132 (47)

0.10

 Oral corticosteroids

33 (8)

29 (3)

0.001

12 (3)

15 (4)

0.75

 Inhaled corticosteroids§

153 (25)

122 (30)

0.14

55 (19)

81 (32)

0.01

 Other control medications||

53 (9)

63 (14)

0.19

15 (8)

33 (10)

0.50

Asthma phenotype

 AwObesity

339 (49)

–

 

112 (38)

227 (76)

< 0.001

 B-Eos-high

237 (36)

–

 

61 (22)

176 (62)

< 0.001

 B-Eos&FeNO-low

157 (26)

–

 

74 (30)

83 (30)

0.95

 FeNO-high

110 (18)

–

 

18 (8)

92 (34)

< 0.001

 AwCOPD

57 (8)

–

 

6 (2)

51 (17)

< 0.001

 Non-classified††

77 (14)

–

 

–

–

 
  1. Data presented as absolute numbers and proportions weighted for the U.S. population. p values < 0.05 are presented in italic
  2. Yrs years, BMI body mass index, Q1 first quartile, Q3 third quartile, BMI body mass index, AwObesity Asthma with obesity, AwCOPD Asthma with concurrent COPD
  3. * Chi square test or Mann–Whitney U-test was used
  4. †Seventy seven subjects included in the “non-classified” group were considered as missing
  5. ‡Prescribed medication taken in the past 30 days
  6. §Alone or in combination with long-acting inhaled β2-agonist
  7. ||Included long-acting inhaled β2-agonist (without corticosteroids), leukotriene inhibitors, and mast cell stabilizers
  8. **Short-acting β2-agonist and/or anticholinergic
  9. ††Subjects with non-single and non-multiple asthma phenotype
Back to article page

Clinical and Translational Allergy

ISSN: 2045-7022

Contact us